Welcome to our dedicated page for Nanovibronix SEC filings (Ticker: NAOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ENvue Medical Inc. filings document the public-company transition from NanoVibronix Inc. and NAOV to the ENvue Medical name and FEED trading symbol, along with capital-structure and governance disclosures. Recent Form 8-K reports cover the completed certificate amendment for the name change, amendments to Series H Convertible Preferred Stock rights, material definitive agreements and security-holder rights.
The filing record also includes proxy materials for annual meeting matters, board and committee changes, registered direct offering documents involving common stock and prefunded warrants, and a late-filing notification for a quarterly report. These documents frame the company’s disclosure record around medical-technology operations, equity financing, preferred-stock terms, Nasdaq-listed common stock, corporate governance and periodic reporting obligations.
ENvue Medical, Inc. registers the resale by a selling stockholder of up to 6,000,768 shares of common stock issuable upon conversion of 6,254 shares of Series H Convertible Preferred Stock at a current conversion price of $1.0422. The company will not receive proceeds from resales. As of April 30, 2026, 5,246,513 shares were outstanding; issuance of the full Conversion Shares would represent approximately 53.4% of outstanding shares as of that date. The prospectus notes Nasdaq listing risks, anti-dilution mechanics, cumulative dividend terms on the Series H, and broad resale methods permitted for the selling holder.
ENvue Medical, Inc. registers the resale by a selling stockholder of up to 6,000,768 shares of common stock issuable upon conversion of 6,254 shares of Series H Convertible Preferred Stock at a current conversion price of $1.0422. The company will not receive proceeds from resales. As of April 30, 2026, 5,246,513 shares were outstanding; issuance of the full Conversion Shares would represent approximately 53.4% of outstanding shares as of that date. The prospectus notes Nasdaq listing risks, anti-dilution mechanics, cumulative dividend terms on the Series H, and broad resale methods permitted for the selling holder.
ENvue Medical, Inc. reported a significantly weaker quarter for the three months ended March 31, 2026, with revenues of $653,000 compared with $1,025,000 a year earlier, mainly due to the removal of its higher-margin PainShield Ultra product from the market.
The company generated a gross loss of $55,000 versus a gross profit of $369,000 last year, as margins were pressured by inventory write-downs and amortization of intangibles from the ENvue merger. Operating expenses rose to $3.7 million, driven by higher selling, marketing, and general and administrative costs tied to integrating and commercializing ENvue’s enteral feeding systems.
Net loss widened to $3.8 million, while net loss available to common stockholders reached $22.6 million after recognizing large deemed dividends and down-round adjustments on Series H preferred stock. Cash and cash equivalents fell to $2.2 million, with $4.3 million used in operating activities during the quarter, and the company discloses substantial doubt about its ability to continue as a going concern without additional financing.
ENvue Medical, Inc. reported a significantly weaker quarter for the three months ended March 31, 2026, with revenues of $653,000 compared with $1,025,000 a year earlier, mainly due to the removal of its higher-margin PainShield Ultra product from the market.
The company generated a gross loss of $55,000 versus a gross profit of $369,000 last year, as margins were pressured by inventory write-downs and amortization of intangibles from the ENvue merger. Operating expenses rose to $3.7 million, driven by higher selling, marketing, and general and administrative costs tied to integrating and commercializing ENvue’s enteral feeding systems.
Net loss widened to $3.8 million, while net loss available to common stockholders reached $22.6 million after recognizing large deemed dividends and down-round adjustments on Series H preferred stock. Cash and cash equivalents fell to $2.2 million, with $4.3 million used in operating activities during the quarter, and the company discloses substantial doubt about its ability to continue as a going concern without additional financing.
ENvue Medical, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company stated it needs additional time to prepare and analyze supporting documentation and anticipates filing the Form 10-Q no later than the fifth calendar day following the prescribed due date. The notice was signed by CEO Doron Besser, M.D. on May 15, 2026.
ENvue Medical, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company stated it needs additional time to prepare and analyze supporting documentation and anticipates filing the Form 10-Q no later than the fifth calendar day following the prescribed due date. The notice was signed by CEO Doron Besser, M.D. on May 15, 2026.
ENvue Medical, Inc., formerly NanoVibronix, filed its annual report describing a major 2025 merger and a shift to a dual-business medical device model. The company acquired ENvue Medical Holdings, adding an enteral feeding navigation platform alongside its legacy ultrasound-based PainShield and UroShield therapies.
Following the merger, ENvue operates through Israeli subsidiary Nano OpCo for pain and biofilm-related devices, and ENvue Medical Holdings LLC for electromagnetic navigation-guided enteral feeding systems and related disposables. The company executed 1‑for‑11 and 1‑for‑10 reverse stock splits in 2025 and reported approximately $7.3 million aggregate market value of voting stock held by non‑affiliates and 3,700,908 common shares outstanding.
ENvue Medical, Inc., formerly NanoVibronix, filed its annual report describing a major 2025 merger and a shift to a dual-business medical device model. The company acquired ENvue Medical Holdings, adding an enteral feeding navigation platform alongside its legacy ultrasound-based PainShield and UroShield therapies.
Following the merger, ENvue operates through Israeli subsidiary Nano OpCo for pain and biofilm-related devices, and ENvue Medical Holdings LLC for electromagnetic navigation-guided enteral feeding systems and related disposables. The company executed 1‑for‑11 and 1‑for‑10 reverse stock splits in 2025 and reported approximately $7.3 million aggregate market value of voting stock held by non‑affiliates and 3,700,908 common shares outstanding.
ENvue Medical, Inc. reports an amended Schedule 13G showing 0.0% ownership by Bank of America Corporation. The filing states 14 shares beneficially owned with 14 shares of shared voting and dispositive power. The beneficial ownership calculation cites December 5, 2025 outstanding share totals of 1,088,192 from a Form 424B3 prospectus.
ENvue Medical, Inc. reports an amended Schedule 13G showing 0.0% ownership by Bank of America Corporation. The filing states 14 shares beneficially owned with 14 shares of shared voting and dispositive power. The beneficial ownership calculation cites December 5, 2025 outstanding share totals of 1,088,192 from a Form 424B3 prospectus.
ENvue Medical, Inc. reported that Nicole M. Fernandez-McGovern, the company’s Interim CFO, filed an initial statement of beneficial ownership on Form 3. This filing establishes her official insider status and discloses her equity position in the company as required for officers under SEC rules.
ENvue Medical, Inc. reported that Nicole M. Fernandez-McGovern, the company’s Interim CFO, filed an initial statement of beneficial ownership on Form 3. This filing establishes her official insider status and discloses her equity position in the company as required for officers under SEC rules.
Envue Medical, Inc. insider Christian Michael Glibert, a more than 10% owner, reports beneficial ownership of 240,000 shares of common stock held directly as of January 14, 2026. The company states there were 1,088,192 shares of common stock outstanding as of February 2026; this is a baseline figure, not the amount reported as owned.
Envue Medical, Inc. insider Christian Michael Glibert, a more than 10% owner, reports beneficial ownership of 240,000 shares of common stock held directly as of January 14, 2026. The company states there were 1,088,192 shares of common stock outstanding as of February 2026; this is a baseline figure, not the amount reported as owned.
ENvue Medical 10% owner Christian Michael Glibert bought 240,000 common shares in the open market. The purchase on January 14, 2026 was at a weighted average price of $2.67 per share, with individual trades ranging from $2.47 to $2.90.
Following this transaction, Glibert directly owns 240,000 shares of ENvue Medical common stock. A footnote states that the ownership percentage is calculated against 1,088,192 shares of common stock outstanding as of the issuer’s most recent February 2026 filings, indicating this is a meaningful stake.
ENvue Medical 10% owner Christian Michael Glibert bought 240,000 common shares in the open market. The purchase on January 14, 2026 was at a weighted average price of $2.67 per share, with individual trades ranging from $2.47 to $2.90.
Following this transaction, Glibert directly owns 240,000 shares of ENvue Medical common stock. A footnote states that the ownership percentage is calculated against 1,088,192 shares of common stock outstanding as of the issuer’s most recent February 2026 filings, indicating this is a meaningful stake.
ENvue Medical, Inc. shareholder Christian Michael Glibert filed a Schedule 13D disclosing beneficial ownership of 240,000 shares of common stock, representing about 22.05% of the company based on 1,088,192 shares outstanding as of February 2026. On January 14, 2026, he purchased 240,000 shares in an open market transaction at an average price of $2.67 per share, using personal funds totaling approximately $640,737.85. He states the shares were acquired for investment purposes and that he may buy more or sell some in the future, but reports no current plans for corporate actions and no contracts or arrangements with others regarding the issuer’s securities.
ENvue Medical, Inc. shareholder Christian Michael Glibert filed a Schedule 13D disclosing beneficial ownership of 240,000 shares of common stock, representing about 22.05% of the company based on 1,088,192 shares outstanding as of February 2026. On January 14, 2026, he purchased 240,000 shares in an open market transaction at an average price of $2.67 per share, using personal funds totaling approximately $640,737.85. He states the shares were acquired for investment purposes and that he may buy more or sell some in the future, but reports no current plans for corporate actions and no contracts or arrangements with others regarding the issuer’s securities.